Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Viola W Zhu

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
JTO Clinical and Research Reports|September 30, 2021
Identification of Novel <i>CDH1-NRG2</i>α and <i>F11R-NRG2α</i> Fusions in NSCLC Plus Additional Novel <i>NRG2α</i> Fusions in Other Solid Tumors by Whole Transcriptome SequencingSai-Hong Ignatius Ou, Joanne Xiu, Misako Nagasaka, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?Sai-Hong Ignatius Ou, Thomas K Lee, Lauren Young, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2020
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world studyGuangjian Yang, Jun Li, Haiyan Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001Caroline E McCoach, Christian Rolfo, Alexander Drilon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLCViola W Zhu, Yen-Ting Lin, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2018
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase InhibitorsAlexa B Schrock, Viola W Zhu, Wen-Son Hsieh, et al.
JTO Clinical and Research Reports|November 25, 2022
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective StudyDavid J Benjamin, Shuai Chen, Joanna B Eldredge, et al.
Future Oncology (London, England)|December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i>-amplified NSCLC and first-line osimertinib resistanceEgbert F Smit, Christophe Dooms, Jo Raskin, et al.
JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
JTO Clinical and Research Reports|September 30, 2021
Identification of Novel <i>CDH1-NRG2</i>α and <i>F11R-NRG2α</i> Fusions in NSCLC Plus Additional Novel <i>NRG2α</i> Fusions in Other Solid Tumors by Whole Transcriptome SequencingSai-Hong Ignatius Ou, Joanne Xiu, Misako Nagasaka, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?Sai-Hong Ignatius Ou, Thomas K Lee, Lauren Young, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2020
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world studyGuangjian Yang, Jun Li, Haiyan Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001Caroline E McCoach, Christian Rolfo, Alexander Drilon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK InhibitorsJessica J Lin, Adam J Schoenfeld, Viola W Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLCViola W Zhu, Yen-Ting Lin, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2018
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase InhibitorsAlexa B Schrock, Viola W Zhu, Wen-Son Hsieh, et al.
JTO Clinical and Research Reports|November 25, 2022
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective StudyDavid J Benjamin, Shuai Chen, Joanna B Eldredge, et al.
Future Oncology (London, England)|December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i>-amplified NSCLC and first-line osimertinib resistanceEgbert F Smit, Christophe Dooms, Jo Raskin, et al.
JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
Pageof 5